- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01411709
A Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress
A Pilot Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress Assessed Under Laboratory Conditions And In Everyday Life
A pilot investigation into the stress relieving properties of Vitano® which will assess the following hypotheses
Individuals exposed to Vitano® will demonstrate diminished blood pressure and heart rate responses to mental stress compared to individuals in the control condition
Physiological recovery (BP, HR and cortisol) from mental stress will be enhanced in individuals exposed to Vitano® compared to individuals in the control condition
Vitano® will have positive effects on cognitive functioning.
Subjective ratings of stress will be reduced in individuals exposed to Vitano® compared to individuals in the control condition
There will be a significant improvement in subjective well-being in individuals taking Vitano®.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Surrey
-
Guildford, Surrey, United Kingdom, GU2 7XP
- University of Surrey
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- subject is able to read and understand the Informed Consent Form (ICF), and understand study procedures.
- The subject has signed the ICF.
- Healthy male or female subjects aged 18-35 years inclusive. Attempts will be made to achieve an equal gender ratio through appropriate screening procedures, but a failure to do so will not preclude analysis of the final data set.
- A score above 30 on the Spielberger State-Trait Anxiety Inventory (STAI).
- The subject agrees to use suitable methods of contraception during the study and for 3 months afterwards.
- The subject is a non-smoker.
- The subject is, in the opinion of the Investigator, healthy on the basis of medical history, vital signs, and the results of routine laboratory tests.
Exclusion Criteria:
- The subject is pregnant or breast feeding.
- The subject consumes more than 5 caffeine-containing beverages per day.
- The subject is colour blind.
- Clinically significant hepatic or renal abnormality as determined by laboratory tests.
- BMI above 33.
- History of alcohol, narcotic, benzodiazepine, or other substance abuse or dependence within the 12 months preceding Visit 1.
- Positive alcohol breath test at any visit. A repeat test will not be allowed. [NOTE: subjects must be told to avoid consumption of alcoholic beverages for at least 24 hours prior to attending the Centre].
- Use of any other medication which may interfere with study outcome and/or interfere with IMP within the 2 weeks or 5 half lives preceding the first treatment phase, with the exception of contraceptive pill, non-steroidal analgesics, and paracetamol. [NOTE: Concomitant medications which do not influence study outcome and/or do not interfere with IMP may be allowed at the discretion of the Investigator].
- Current participation in another clinical trial with an investigational or non-investigational drug or device, or participation in another clinical trial within the 3 months preceding Visit 1 (screening visit).
- Any condition that, in the Investigator's opinion, compromises the subject's ability to meet protocol requirements or to complete the study.
- Moderate or severe anxiety* *If participants are found to have moderate or severe anxiety during the screening process then they will be referred to the University Counselling service.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vitano
|
two 200mg tablets per day for 14 days
|
No Intervention: Control
No tablets - control group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood pressure measurements
Time Frame: Measurements over 14 days (Day 0, Day 7 and Day 14)
|
Blood pressure readings taken under laboratory conditions during cognitive testing and relaxation periods
|
Measurements over 14 days (Day 0, Day 7 and Day 14)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measures of cognitive function
Time Frame: 14 days
|
cognitive function assessed four times during the 14 day study period
|
14 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRC287
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Stress/Anxiety
-
Logan College of ChiropracticCompletedAnxiety, Mild to ModerateUnited States
-
NestléCompletedMild to Moderate Levels of StressSwitzerland
-
Karolinska InstitutetCompletedStress, Psychological | Sleep Disturbance | Anxiety State | Mild Depression
-
University of Texas at AustinFreespira, Inc.RecruitingAnxiety Disorders | Generalized Anxiety Disorder | Trauma | Posttraumatic Stress Disorder | Social Anxiety Disorder | Panic Disorder | Agoraphobia | Illness Anxiety Disorder | Acute Stress Disorder | Adjustment Disorder With Anxious MoodUnited States
-
Sherry StewartCanadian Institutes of Health Research (CIHR); Dalhousie University; University...UnknownMajor Depression | Social Anxiety | Panic Disorder | Generalized Anxiety | Stress Disorder, Posttraumatic
-
Basque Health ServiceUnknownAnxiety-depressive Patients Mild to ModerateSpain
-
University of Massachusetts, AmherstVanderbilt UniversityRecruitingDepression | Stress, Psychological | Anxiety | Stress, PhysiologicalUnited States
-
University of WashingtonNational Institute of Mental Health (NIMH)CompletedGeneralized Anxiety Disorder | Social Anxiety Disorder | Panic Disorder | Post-traumatic Stress DisorderUnited States
-
National Nutrition and Food Technology InstituteUnknownPatients With Mild to Moderate GAD
-
prof. Peter de JongeUnknownAnxiety Disorders | Generalized Anxiety Disorder | Social Anxiety Disorder | Panic Disorder | Post-traumatic Stress Disorder | Obsessive-compulsive Disorder